Patent application number | Description | Published |
20100286223 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors - Bicyclo-pyrazole compound of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, processes for their preparation, combinatorial libraries comprising a plurality of them and pharmaceutical compositions thereof, are herewith disclosed: the compounds of the invention are useful, in therapy, as protein kinase inhibitors, for instance in the treatment of cancer. | 11-11-2010 |
20120165311 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS - Thieno[2,3-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 06-28-2012 |
Patent application number | Description | Published |
20080253987 | POLYMERIC TISSUE SEALANT - Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:
| 10-16-2008 |
20100034769 | COMPOSITIONS FOR TISSUE AUGMENTATION - Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty). | 02-11-2010 |
20100284919 | Injectable Radio-Opaque Compositions for Tissue Augmentation - Injectable radio-opaque compositions for tissue augmentation and in particular hard tissue augmentation, and kits and methods of using thereof are described herein. The injectable compositions form porous, biologically degradable, fibrin matrices. The compositions are formed from fibrinogen, thrombin or another agent that causes the fibrinogen to crosslink, and strontium salts. Optionally an iodinated contrast agent is further incorporated in the composition. In certain aspects, the compositions have substantially no exothermicity when forming the matrix and the resulting matrices exhibit mechanical properties typically seen in elastomers. Adequate radio-opacity is achieved through the incorporation of strontium salts in combination or not with iodinated contrast agents. | 11-11-2010 |
20150133579 | Polymeric Tissue Sealant - Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:
| 05-14-2015 |
Patent application number | Description | Published |
20090099199 | ORGANIC COMPOUNDS - The invention relates to compound of the formula I | 04-16-2009 |
20090143337 | C2-C5-Alkyl-Imidazole-Bisphosphonates | 06-04-2009 |
20100222396 | 4-ARYL-BUTANE-1,3-DIAMIDES - The invention relates to compound of the formula I | 09-02-2010 |
20110224173 | C2-C5-Alkyl-Imidazole-Bisphosphonates | 09-15-2011 |
20110257131 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS - (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, | 10-20-2011 |
20110288057 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS - The invention relates to the use of and mainly novel compounds of the formula I | 11-24-2011 |
20120094958 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE - The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof. | 04-19-2012 |
20120101110 | Diaza-spiro[5.5]undecanes - The invention relates to compound of the formula I | 04-26-2012 |
20120165331 | Di/tri-aza-spiro-C9-C11alkanes - The invention relates to compounds of the formula I | 06-28-2012 |
20120258973 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES - The invention relates to compound of the formula (I′) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. | 10-11-2012 |
20120264748 | DIAZA-SPIRO[5.5]UNDECANES - The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. | 10-18-2012 |
20130281463 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. | 10-24-2013 |
20130317024 | PYRROLOPYRROLIDINONE COMPOUNDS - The invention relates to compounds of formula (I): | 11-28-2013 |
20140349990 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; | 11-27-2014 |
20160095843 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-07-2016 |
20160096843 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-07-2016 |
20160102107 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-14-2016 |
Patent application number | Description | Published |
20100210631 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases. | 08-19-2010 |
20130274249 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. | 10-17-2013 |
20130289122 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. | 10-31-2013 |
20150157598 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157599 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157600 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157601 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157602 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
Patent application number | Description | Published |
20130282380 | Method And System For Facilitating Communications For A User Transaction - Current human-to-machine interfaces enable users to interact with a company's database and enter into a series of transactions (e.g., purchasing products/services and paying bills). Each transaction may require several operations or stages requiring user input or interaction. Some systems enable a user to enter a voice input parameter providing multiple operations of instruction (e.g., single natural language command). However, users of such a system do not know what types of commands the system is capable of accepting. Embodiments of the present invention facilitate communications for user transactions by determining a user's goal transaction and presenting a visual representation of a voice input parameter for the goal transaction. The use of visual representations notifies the user of the system's capability of accepting single natural language commands and the types of commands the system is capable of accepting, thereby enabling a user to complete a transaction in a shorter period of time. | 10-24-2013 |
20140253455 | TASK ASSISTANT PROVIDING CONTEXTUAL SUGGESTIONS - A method of providing a task assistant to provide an interface to an application is described. The method comprises, in one embodiment, providing a task assistant to provide an interface to an application, to receive input from a user through multimodal input including a plurality of speech input, typing input, and touch input. The method further comprises receiving a request from a user for a suggestion, determining a current transaction state, based on interactions with the user during a current session, and selecting suggestions relevant to a transaction type associated with the current transaction state. | 09-11-2014 |
20140257792 | Anaphora Resolution Using Linguisitic Cues, Dialogue Context, and General Knowledge - An automatic conversational system has multiple computer-implemented dialogue components for conducting an automated dialogue process with a human user. A user client delivers dialogue output prompts to the human user and receives dialogue input responses from the human user including speech inputs. An automatic speech recognition engine processes the speech inputs to determine corresponding sequences of representative text words. A natural language understanding (NLU) processing arrangement processes the dialogue input responses and the text words to determine corresponding semantic interpretations. The NLU processing arrangement includes an anaphora processor that accesses different information sources characterizing dialogue context, linguistic features, and NLU features to identify unresolved anaphora in the text words needing resolution in order to determine a semantic interpretation. A dialogue manager manages the dialogue process with the human user based on the semantic interpretations. | 09-11-2014 |
20140257793 | Communicating Context Across Different Components of Multi-Modal Dialog Applications - A human-machine dialogue system is described which has multiple computer-implemented dialogue components. A user client delivers output prompts to a human user and receives dialogue inputs including speech inputs from the human user. An automatic speech recognition (ASR) engine processes the speech inputs to determine corresponding sequences of representative text words. A natural language understanding (NLU) engine processes the text words to determine corresponding semantic interpretations. A dialogue manager (DM) generates the output prompts and responds to the semantic interpretations so as to manage a dialogue process with the human user. The dialogue components share context information with each other using a common context sharing mechanism such that the operation of each dialogue component reflects available context information. | 09-11-2014 |
20140257794 | Semantic Re-Ranking of NLU Results in Conversational Dialogue Applications - A human-machine dialogue system is described which has multiple computer-implemented dialogue components. A user client delivers output prompts to a human user and receives dialogue inputs from the human user including speech inputs. An automatic speech recognition (ASR) engine processes the speech inputs to determine corresponding sequences of representative text words. A natural language understanding (NLU) engine processes the text words to determine corresponding NLU-ranked semantic interpretations. A semantic re-ranking module re-ranks the NLU-ranked semantic interpretations based on at least one of dialogue context information and world knowledge information. A dialogue manager responds to the re-ranked semantic interpretations and generates the output prompts so as to manage a dialogue process with the human user. | 09-11-2014 |
20140258324 | TASK ASSISTANT UTILIZING CONTEXT FOR IMPROVED INTERACTION - A method of providing a task assistant is described. The task assistant is designed to receive input from a user through multimodal input including a plurality of speech input, typing input, and touch input, determine the meaning of the input, and determining whether there is a context based on prior interactions with the user. The method further to generate an interpreted input based on a combination of the input and the context, and providing a formatted query to an application. The method further to receive data from the application in response to the formatted query, and provide a response to the user through multimodal output including a plurality of: speech output, text output, non-speech audio output, haptic output, and visual non-text output. The method further to update the context based on the interpreted input. | 09-11-2014 |
20140258855 | TASK ASSISTANT INCLUDING IMPROVED NAVIGATION - A method of providing a task assistant to provide an interface to an application is described. The method includes, in one embodiment, receiving input from a user through multimodal input including a plurality of each input, typing input, and touch input, interpreting the input, and providing a formatted query to the application, and receiving data from the application in response to the query. The method further includes identifying a destination providing a response to the query, identifying an anchor pointing to a specific location in the application associated with the response to the query, and directing the user to the specific location, using the anchor, the specific location providing a response to the user. | 09-11-2014 |
20140309990 | SEMANTIC RE-RANKING OF NLU RESULTS IN CONVERSATIONAL DIALOGUE APPLICATIONS - Multiple natural language understanding (NLU) interpretation selection models may be generated. The NLU interpretation selection models may include a generic NLU interpretation selection model that is not specialized for a specific set of NLU interpretations type and one or more specialized NLU interpretation selection models, each of which may be specific to a particular set of NLU interpretations type. The specialized NLU interpretation selection model(s) may be utilized to process natural language input data comprising data corresponding to their respective sets of NLU interpretations type(s). The generic NLU interpretation selection model may be utilized to process natural language input data comprising data that does not correspond to the sets of NLU interpretations type(s) associated with the specialized NLU interpretation selection model(s). | 10-16-2014 |
20150046168 | Method and Apparatus for a Multi I/O Modality Language Independent User-Interaction Platform - Automated user-machine interaction is gaining attraction in many applications and services. However, implementing and offering smart automated user-machine interaction services still present technical challenges. According to at least one example embodiment, a dialogue manager is configured to handle multiple dialogue applications independent of the language, the input modalities, or output modalities used. The dialogue manager employs generic semantic representation of user-input data. At a step of a dialogue, the dialogue manager determines whether the user-input data is indicative of a new request or a refinement request based on the generic semantic representation and at least one of a maintained state of the dialogue, general knowledge data representing one or more concepts, and data representing history of the dialogue. The dialogue manager then responds to determined user-request with multi-facet output data to a client dialogue application indicating action(s) to be performed. | 02-12-2015 |
20160070695 | Method And Apparatus For A Multi I/O Modality Language Independent User-Interaction Platform - Automated user-machine interaction is gaining attraction in many applications and services. However, implementing and offering smart automated user-machine interaction services still present technical challenges. According to at least one example embodiment, a dialogue manager is configured to handle multiple dialogue applications independent of the language, the input modalities, or output modalities used. The dialogue manager employs generic semantic representation of user-input data. At a step of a dialogue, the dialogue manager determines whether the user-input data is indicative of a new request or a refinement request based on the generic semantic representation and at least one of a maintained state of the dialogue, general knowledge data representing one or more concepts, and data representing history of the dialogue. The dialogue manager then responds to determined user-request with multi-facet output data to a client dialogue application indicating action(s) to be performed. | 03-10-2016 |
Patent application number | Description | Published |
20090159969 | PROCESS FOR MANUFACTURING A SEMICONDUCTOR POWER DEVICE COMPRISING CHARGE-BALANCE COLUMN STRUCTURES AND RESPECTIVE DEVICE - Process for manufacturing a semiconductor power device, wherein a trench is formed in a semiconductor body having a first conductivity type; the trench is annealed for shaping purpose; and the trench is filled with semiconductor material via epitaxial growth so as to obtain a first column having a second conductivity type. The epitaxial growth is performed by supplying a gas containing silicon and a gas containing dopant ions of the second conductivity type in presence of a halogenide gas and occurs with uniform distribution of the dopant ions. The flow of the gas containing dopant ions is varied according to a linear ramp during the epitaxial growth; in particular, in the case of selective growth of the semiconductor material in the presence of a hard mask, the flow decreases; in the case of non-selective growth, in the absence of hard mask, the flow increases. | 06-25-2009 |
20100154876 | MODULAR INTERDIGITATED BACK CONTACT PHOTOVOLTAIC CELL STRUCTURE ON OPAQUE SUBSTRATE AND FABRICATION PROCESS - A back contact integrated photovoltaic cell includes a substrate having a dielectric surface and a patterned metal layer with parallel spaced alternately positive and negative electrode fingers forming an interdigitated two-terminal structure over the dielectric surface of the substrate. A dielectric filler may be in the interstices of separation between adjacent spaced parts of the patterned metal layer. Parallel spaced strips, alternately of p | 06-24-2010 |
20120319191 | PROCESS FOR MANUFACTURING A SEMICONDUCTOR POWER DEVICE COMPRISING CHARGE-BALANCE COLUMN STRUCTURES AND RESPECTIVE DEVICE - Process for manufacturing a semiconductor power device, wherein a trench is formed in a semiconductor body having a first conductivity type; the trench is annealed for shaping purpose; and the trench is filled with semiconductor material via epitaxial growth so as to obtain a first column having a second conductivity type. The epitaxial growth is performed by supplying a gas containing silicon and a gas containing dopant ions of the second conductivity type in presence of a halogenide gas and occurs with uniform distribution of the dopant ions. The flow of the gas containing dopant ions is varied according to a linear ramp during the epitaxial growth; in particular, in the case of selective growth of the semiconductor material in the presence of a hard mask, the flow decreases; in the case of non-selective growth, in the absence of hard mask, the flow increases. | 12-20-2012 |
20150325640 | PROCESS FOR MANUFACTURING A SEMICONDUCTOR POWER DEVICE COMPRISING CHARGE-BALANCE COLUMN STRUCTURES AND RESPECTIVE DEVICE - Process for manufacturing a semiconductor power device, wherein a trench is formed in a semiconductor body having a first conductivity type; the trench is annealed for shaping purpose; and the trench is filled with semiconductor material via epitaxial growth so as to obtain a first column having a second conductivity type. The epitaxial growth is performed by supplying a gas containing silicon and a gas containing dopant ions of the second conductivity type in presence of a halogenide gas and occurs with uniform distribution of the dopant ions. The flow of the gas containing dopant ions is varied according to a linear ramp during the epitaxial growth; in particular, in the case of selective growth of the semiconductor material in the presence of a hard mask, the flow decreases; in the case of non-selective growth, in the absence of hard mask, the flow increases. | 11-12-2015 |
Patent application number | Description | Published |
20090169534 | Variant Forms of Urate Oxidase and Use Thereof - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 07-02-2009 |
20090209021 | Variant Form of Urate Oxidase and Use Thereof - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 08-20-2009 |
20110104751 | VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 05-05-2011 |
20110217755 | VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 09-08-2011 |
20120070876 | VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 03-22-2012 |
20120225046 | VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 09-06-2012 |
20120309085 | Variant Forms of Urate Oxidase and Use Thereof - Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described. | 12-06-2012 |
20130330803 | Variant Forms of Urate Oxidase and Use Thereof - Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described. | 12-12-2013 |
20150197732 | VARIANT FORMS OF URATE OXIDASE AND USE THEREOF - Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described. | 07-16-2015 |
Patent application number | Description | Published |
20130096560 | BONE PLATE FIXATION SYSTEM - A universal jig is compatible with bone plates of varying size, in which different plate sizes having different hole configurations. For example, a longer bone plate may have a first hole pattern along a given length thereof, while various shorter bone plates may have differing hole patterns along respective corresponding lengths. The universal jig includes a combination of hole groupings to provide a jig hole for each hole in the differing hole patterns of the longer and shorter plates, so that the universal jig is useable with a variety of bone plates having disparate hole patterns. For any given bone plate length and hole configuration, a masking cover may provided to attach to the jig. The masking cover masks off unused jig holes, so that only those jig holes intended for use with a particular bone plate are left exposed. | 04-18-2013 |
20140336713 | PERIPROSTHETIC BONE PLATES - The present disclosure relates to bone plates that are configured for use with bones having periprosthetic fractures. For example, in the event that a proximal femur is fractured in an area that is adjacent to a prosthetic component, such as a femoral stem used in a hip replacement, the periprosthetic bone plates of the present invention may be used. In one exemplary embodiment, the periprosthetic bone plates include a periprosthetic zone having a plurality of central apertures and a plurality of outer apertures that are offset from the central apertures. The periprosthetic zone may further include a plurality of indentations, each indentation extending longitudinally between adjacent outer apertures to narrow a width of the bone plate. | 11-13-2014 |
Patent application number | Description | Published |
20090247465 | Novel Use of Bivalirudin in the Treatment of Acute Coronary Syndrome - A method of treating acute coronary syndrome (ACS) in a patient, comprising administering a therapeutically effective amount of an indirect thrombin inhibitor to the patient, and subsequently administering a therapeutically effective amount of a direct thrombin inhibitor to the patient wherein the direct thrombin inhibitor is administered prior to and during an invasive bodily procedure. | 10-01-2009 |
20110288043 | MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY - A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other genera! surgical procedure. | 11-24-2011 |
Patent application number | Description | Published |
20110112030 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS - The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation. | 05-12-2011 |
20130190265 | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events - Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y | 07-25-2013 |
20130303477 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-14-2013 |
20130303478 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-14-2013 |
20130316968 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-28-2013 |
20130324492 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 12-05-2013 |
20140107032 | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events - Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y | 04-17-2014 |
20150038449 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 02-05-2015 |
20150099716 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 04-09-2015 |
Patent application number | Description | Published |
20100330338 | STRUCTURED MATERIAL SUBSTRATES FOR FLEXIBLE, STRETCHABLE ELECTRONICS - A flexible and stretchable patterned substrate is provided having a strain-permitting material comprising a patterned conformation that allows the flexible patterned substrate to experience local strain or local strain domains lower than the macroscopic strain of the flexible and stretchable patterned substrate. | 12-30-2010 |
20110059291 | STRUCTURED MATERIALS WITH TAILORED ISOTROPIC AND ANISOTROPIC POISSON'S RATIOS INCLUDING NEGATIVE AND ZERO POISSON'S RATIOS - The invention described herein relates to structured porous materials, where the porous structure provides a tailored Poisson's ratio behavior. In particular, the structures of this invention are tailored to provide a range in Poisson's ratio ranging from a negative Poisson's ratio to a zero Poisson's. Two exemplar structures, each consisting of a pattern of elliptical or elliptical-like voids in an elastomeric sheet, are presented. The Poisson's ratios are imparted to the substrate via the mechanics of the deformation of the voids (stretching, opening, and closing) and the mechanics of the material (rotation, translation, bending, and stretching). The geometry of the voids and the remaining substrate are not limited to those presented in the models and experiments of the exemplars, but can vary over a wide range of sizes and shapes. The invention applies to both two-dimensional structured materials as well as three dimensionally structured materials. | 03-10-2011 |
20150047113 | STRUCTURED MATERIAL FOR IMPACT PROTECTION - A structured material for impact protection includes a plurality of tubular members formed from a thermoplastic elastomer material. The plurality of tubular members are arranged in a bundle such that the central axes of the plurality of tubular members are substantially parallel, and adjacent tubular members are secured to one another along their length. A method of forming a structured impact protection material includes arranging a plurality of tubes formed from a thermoplastic elastomer material into a selected shape. The tubes are arranged in a layer with central axes of the plurality of tubes aligned to be parallel to each other. Heat is applied to adjacent first end portions of tubes of plurality of tubes and the adjacent first end portions are secured to each other via thermal bond. Heat is applied to adjacent second end portions of the tubes and the adjacent second end portions are secured to each other via thermal bond. | 02-19-2015 |
Patent application number | Description | Published |
20100099730 | ANNELLATED PYRROLE COMPOUNDS FOR CANCER MANAGEMENT - The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e.g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same. This treatment ameliorates, diminishes, actively treats, reverses or prevents any disease related to insufficient apoptosis, in particular neoplasia, and it may be combined with irradiation, heating and treatment with a cytotoxic agent for preventive and/or curative purposes. | 04-22-2010 |
Patent application number | Description | Published |
20080207764 | Novel Benzamidine Derivatives Having Anti-Inflammatory and Immunosuppressive Activity - Compounds which can be represented by the general formula (I) indicated below: | 08-28-2008 |
20090264451 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS - The present invention is directed to novel 6-1H-imidazo-2-aryl and 2-heteroaryl quinazoline and quinoline of formula I, corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding pharmaceutical composition for the treatment of pain and inflammatory related disorders. Compounds of the invention have been proven highly effective in the pharmacological treatment of both inflammatory and neuropathic pain, in addition to striking anti-inflammatory properties. Their effectiveness in interfering with COX-2 and inflammatory cytokines expressions and production, highlights them as interesting compounds also for the treatment of cancer in addition to several inflammatory diseases. | 10-22-2009 |
20100120802 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production - Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): | 05-13-2010 |
20110118289 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS - The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: | 05-19-2011 |
20110257209 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS - The present invention is directed to novel 6-1H-imidazo-2-aryl and 2-heteroaryl quinazoline and quinoline of formula I, corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding pharmaceutical composition for the treatment of pain and inflammatory related disorders. Compounds of the invention have been proven highly effective in the pharmacological treatment of both inflammatory and neuropathic pain, in addition to striking anti-inflammatory properties. Their effectiveness in interfering with COX-2 and inflammatory cytokines expressions and production, highlights them as interesting compounds also for the treatment of cancer in addition to several inflammatory diseases. | 10-20-2011 |